Conditional Replication Adenovirus Sensitizes A549 Cancer Cell to Cisplatin

DOI: 10.4236/eng.2012.410B043   PDF   HTML     3,391 Downloads   4,325 Views  

Abstract

Objective: The aim of the study was to improve the therapeutic effect for lung cancer using a synergetic strategy of adenovirus-based gene therapy combined with chemotherapy. Methods: A conditional replication adenovirus(CRAd) was employed to treat the A549 lung cancer cells and cisplatin-resisted A549(A549-DDP) cells. In vitro MTS / PMS assay were used to evaluate the cell viability. PCR were used to detect expression of Coxsackie receptor (CAR) and Multidrug resistance(MDR) gene. The in vivo anti-tumor effect of CRAd and cisplatin was evaluated using a subcutaneous mouse model. Results: The CRAd sensitizes A549 cancer cells to cisplatin. The mechanism of enhanced cell growth inhibition is associated with the increased CAR and MDR expression. Conclusion: Our approach is better than the conventional gene therapy and chemotherapy strategy.

Share and Cite:

Y. Liu and Y. Huang, "Conditional Replication Adenovirus Sensitizes A549 Cancer Cell to Cisplatin," Engineering, Vol. 4 No. 10B, 2012, pp. 165-166. doi: 10.4236/eng.2012.410B043.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin.2012:62(1):10-29.
[2] Socinski MA, Bogart JA. Limited-stage small-cell lung cancer: the current status of combined-modality therapy. J Clin Oncol 2007,25: 4137-4145.
[3] Wan L,Hyo-Im C,Mi-Jin K, et a.l Depletion ofmitochondrial DNA up-regulates the expression of MDR1 gene via an increase in mRNA stability.Exp.Mo.lMed, 2008, 40(1): 109-117.
[4] Paredes Lario A,Blanco Garcia C et al.Expression of proteins associated with multidrug resistance and resistance to chemotherapy in lung cancer[J].Arch Bronconeumol,2007;43(9):479一484.
[5] Pujol JL,Simony J,Gautier V,et al.Immuno-histochemical study of p-glycoprotein distribution in lung [J].Cancer,1993,10:1.

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.